92results about "Reverse transcribing DNA viruses" patented technology

The invention provides a polypeptide for activating cellular immunity in chronic hepatitis B and application of the polypeptide, and belongs to the technical field of biological medicine. A polypeptide library is designed and synthesized on the basis of a preS1 structural domain for coding HBV large HBsAg, a full-length core protein Core, a polymerase protein fragment rich in T cell epitopes and an mRNA-PreS1CPX holoantigen sequence (as shown in SEQ ID NO.1) of full-length X protein HBX, and peptide fragments capable of activating T cell immunity are screened by utilizing ELISPOT and flow cytometry. Experimental results show that the polypeptide sequences as shown in SEQ ID NO.2-15 can promote HBV antigen specific immune response by stimulating CD8 + T lymphocytes to secrete IFN-gamma, so that immune activation treatment of hepatitis B is realized.

Disclosed herein is a method for enhancing immune response of a vaccine. The method includes preparing a Phycocyanin compound. The Phycocyanin compound includes at least one of C-phycocyanin (C-PC), Phycoerythrin (PE), Allophycocyanin (APC), phycocyanobilin (PCB), and combinations thereof. The method further includes administering the prepared Phycocyanin along with a vaccine composition to a living body.

The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.

The present application relates to the field of biomedicine, and provides an epigenetic editing tool for targeting a hepatitis B virus gene and a use thereof.

The invention provides a construction method of an HBV (Hepatitis B Virus) infection model based on multilineage hepatobiliary organs, which comprises the following steps: differentiating human pluripotent stem cells to form immune cell-containing hepatobiliary organs for further maturation culture, and enabling the hepatobiliary organs to be mature in function and highly express NTCP (Natriuretic Therapeutic Cells) by using a maturation culture medium containing bile metabolism substrate cholesterol and deoxybear bile acid, so as to obtain the HBV infection model based on the multilineage hepatobiliary organs. And then infecting the mature organs by adopting an HBV virus strain generated by HepAD38 cells to construct an in-vitro model which is susceptible to HBV and can maintain an infection state for a long time. According to the construction method, the liver infection and immune interaction microenvironment can be simulated more truly, and a stable and reliable experimental platform is provided for HBV infection mechanism research and anti-HBV drug screening.

Provided herein are methods for administering hepatitis B virus surface antigen (HBsAg) to a subject suffering from chronic hepatitis B to differentiate between responder subjects and non-responder subjects that the administration of HBsAg results in an increased response to HBV antibody levels, and treating chronic hepatitis B in responder subjects using HBV therapy. Also provided are methods of excluding unresponded subjects outside a clinical study.

The present application relates to the field of biomedicine, and provides an epigenetic editing tool for targeting a hepatitis B virus gene and a use thereof.

The present invention provides novel immunogenic peptides derived from the X and polymerase proteins of hepatitis B virus (HBV). These peptides contain epitopes that are well conserved among multiple HBV variants and are derived from regions of the proteins essential for viral replication. Furthermore, these novel HBV antigens bind to multiple HLA types and induce IFN-glucan synthesis in PBMCs from HBV-resolved individuals. γ Epitopes that elicit a response were identified.

A chimeric antigen receptor (CAR), for example a CD19-specific CAR, capable of targeting an antigen expressed on disease-associated cells, such as tumor cells. A polynucleotide encoding the CAR and, optionally: i) an miRNA silencer module capable of inhibiting the expression of an immune checkpoint protein (e.g., PD-1); ii) a cytokine (e.g., membrane-bound IL-15); and / or a cell tag (e.g., a HER-1 kill switch). A vector comprising the polynucleotide. A modified immune effector cell comprising the CAR, polynucleotide, or vector. Compositions and kits comprising the CAR, polynucleotide, vector, and / or modified immune effector cell. Use of the CAR, polynucleotide, vector, and / or modified immune effector cell in the manufacture of a medicament for the treatment of a disease or disorder. A method for treating a subject with a disease or disorder, comprising administering the CAR, polynucleotide, vector, and / or modified immune effector cell to a subject in need thereof.

The present invention relates to compositions and methods for therapeutic immunization for treatment of chronic hepatitis B virus (CHB). Methods of the invention include a method generating a high titer hybrid-hepatitis B virus (HBV) vector, methods of treating and / or preventing HBV infection and / or CHB, and methods of inducing a memory T and B cell immune response against HBV infection in a subject administered the VLV composition produced thereby. Furthermore, the invention encompasses a pharmaceutical composition for vaccinating a subject to protect the subject against infection with HBV.

Pharmaceutical compositions comprising a 4-sulfamoyl-heteroaryl-2-carboxamides that are useful as pregenomic RNA encapsidation inhibitors of HBV for the treatment of Hepatitis B virus (HBV) infection and related conditions are disclosed herein.

Provided are affinity ligands that bind to Hepatitis B surface antigen (HBsAg), affinity resins comprising the HBsAg-binding ligands, and related compositions and methods for the isolation and / or purification of HBsAg.

Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.

The invention provides a space-time controlled recombinant cccDNA transgenic animal model as well as application and a preparation method thereof.

The present disclosure relates to a novel vaccine strategy against hepatitis B virus (HBV) infection, which is a major cause of chronic liver disease and hepatocellular carcinoma worldwide. The disclosure provides fusion proteins that target dendritic cells (DCs), the key antigen-presenting cells of the immune system, and deliver HBV-derived peptides to both the major histocompatibility complex (MHC) class I and II pathways, thereby inducing strong and specific humoral and cellular immune responses against the viral envelope and core antigens. The disclosure also provides methods of using the fusion proteins for the prevention or treatment of HBV infection and its complications. The inventors have demonstrated in a mouse model that the DC-targeting HBV vaccine candidates can elicit robust antibody and T cell responses, which are essential for the clearance of the virus and the protection from chronic infection.

Aspects of the present disclosure include methods and compositions related to therapeutic immune cells having enhanced metabolic fitness. In certain aspects, polynucleotides encoding one or more viral, bacterial, and / or fungal genes capable of manipulating cell metabolism and, optionally, one or more antigen-specific receptors, are disclosed. In some aspects, disclosed are methods for enhancing the metabolic fitness of an immune cell comprising introducing into the immune cell a polynucleotide encoding one or more viral, bacterial, and / or fungal genes capable of manipulating cell metabolism. Cells (e.g., NK cells, T cells) expressing polynucleotides encoding one or more viral, bacterial, and / or fungal genes capable of manipulating cell metabolism and, optionally, one or more antigen-specific receptors are described. Also described are therapeutic methods using polynucleotides of the disclosure.

The present disclosure relates to methods to generate an immune response for the treatment or prevention of hepatitis B virus infection. This disclosure also relates to methods to generate MHC-E and / or MHC-II restricted CD8+ T cells for the treatment or prevention of hepatitis B virus infection.

The invention relates to the technical field of medicine, in particular to an antigen double burst release self-boosting immune vaccine and application thereof.The antigen double burst release self-boosting immune vaccine is characterized in that antigens are loaded inside and outside complex coacervation microcapsules in the vaccine, nanoparticles are prepared through a nanoprecipitation method, the nanoparticles and cell membranes jointly entrap the antigens to form functional nanoparticles, and the functional nanoparticles are used as functional nanoparticles; the preparation method comprises the following steps: coating functionalized nanoparticles by using a micro-fluidic technology and a complex coagulation method to prepare microcapsules, coating the surface of the microcapsules by using dopamine hydrochloride auto-polymerization reaction to form coating microcapsules, and finally blending with the functionalized nanoparticles, thereby dividing the antigen into an inner part and an outer part. After entering a body, the nano-microparticle carrier double burst release vaccine is subjected to antigen double burst release with time lag intervals in different time periods; the prepared vaccine can release antigens firstly, then effectively collect and activate antigen presenting cells, the antigen presenting cells uptake the antigen presenting cells to cause immune response, and the generation of specific antibodies can be effectively induced by two times of antigen release through the time-delay coating, so that a traditional natural immune procedure is simulated.

The present disclosure provides T-cell modulatory multimeric polypeptides that comprise an immunomodulatory polypeptide that exhibits reduced binding affinity to a cognate co-immunomodulatory polypeptide. A T-cell modulatory multimeric polypeptide is useful for modulating the activity of a T cell, and for modulating an immune response in an individual.

Aspects of the present disclosure provides for improved vaccine compositions of ionizable lipid nanoparticles for the delivery of immunogenic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in dendritic cells. In some embodiments, the incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation provided high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage.

The embodiments provided for herein relate to recombinant adenoviruses, wherein the capsid hexon polypeptides of the adenovirus have been modified. Such modifications can comprise the modification of adenovirus strain Ad5 with at least one capsid hexon hypervariable region polypeptide from adenovirus strain Ad57. The embodiments also relate to the modified capsid hexon polypeptides, to nucleic acids encoding the modified capsid hexon polypeptides, and to methods of using the same.

The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.

To provide an immunotherapy to Type B hepatitis virus infection, more specifically, a pharmaceutical composition, a vaccine, and a method for treating Type B hepatitis virus infection.SOLUTION: An infectious arenavirus virus vector in which an arenavirus open reading frame encoding arenavirus glycoprotein in segment S is removed, and which is replaced with a nucleotide sequence selected from the group consisting of: a. a nucleotide sequence encoding HBV pre-S2 / S protein or an antigenic fragment thereof; b. a nucleotide sequence encoding HBV HBc protein or an antigenic fragment thereof; c. a nucleotide sequence encoding HBV polymerase protein or an antigenic fragment thereof; d. a nucleotide sequence encoding HBV HBs protein and HBV HBc protein or a fusion of antigenic fragments thereof; and e. a nucleotide sequence encoding HBV HBe protein or an antigenic fragment thereof.SELECTED DRAWING: Figure 1

The present invention relates to immunogenic compositions and combinations thereof that may find use in immunization regimens for the treatment of chronic hepatitis B. The immunogenic compositions include HBs, HBc, and a replication-deficient chimpanzee adenovirus (ChAd) vector containing a polynucleotide encoding the human invariant chain (hIi) fused to HBc. Another immunogenic composition includes a modified vaccinia virus Ankara (MVA) vector containing a polynucleotide encoding HBs and HBc. Another immunogenic composition includes recombinant HBs, a C-terminally truncated recombinant HBc, and an adjuvant containing MPL and QS-21. [Selection diagram] None

This invention relates to compositions, methods, strategies, and treatment modalities related to the epigenetic modification of hepatitis B virus (HBV) genes.

Provided are HLA-A02 restricted T cell receptors (TCRs) that specifically target HBV surface antigen which is a S20 peptide consisting of FLLTRILTI and the T cells expressing said TCRs. It also relates to the nucleic acid molecules and vectors encoding said TCRs and their medical uses in reducing HBV antigen-positive tumour cells and treating or preventing HBV infections and related diseases.

To provide non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, the HBV polymerase C-terminal domain, and immunogenic fragments thereof.SOLUTION: Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, the HBV polymerase C-terminal domain, and immunogenic fragments thereof. Also provided are HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins.SELECTED DRAWING: Figure 25B

Provided is a hepatitis B vaccine comprising at least one mRNA molecule encoding a hepatitis B antigen and methods of use thereof to treat or prevent hepatitis B.

A composition for treating chronic hepatitis B infection, comprising mRNA encoding a hepatitis B viral antigen, the mRNA being encapsulated in a lipid nanoparticle (LNP).